Pomalidomide
- Generic Name
- Pomalidomide
- Brand Names
- Imnovid, Pomalyst, Imnovid (previously Pomalidomide Celgene), Pomalidomide Viatris, Pomalidomide Zentiva, Pomalidomide Krka, Pomalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C13H11N3O4
- CAS Number
- 19171-19-8
- Unique Ingredient Identifier
- D2UX06XLB5
- Background
Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
- Indication
Pomalidomide is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and have demonstrated disease progression on or within 60 days of completion of the last therapy. It is also indicated for the treatment of Kaposi's sarcoma (KS) in AIDS patients who have failed highly active antiretroviral thera...
- Associated Conditions
- Kaposi's Sarcoma, Multiple Myeloma (MM)
- Associated Therapies
- -
Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2023-12-06
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 380
- Registration Number
- NCT06158841
- Locations
- 🇨🇳
The First Affiliated Hospital, Zhejiang University School of Medicine /ID# 260883, Hangzhou, Zhejiang, China
🇺🇸Alta Bates Summit Medical Center for Research /ID# 261438, Berkeley, California, United States
🇺🇸Providence - St. Jude Medical Center /ID# 262031, Fullerton, California, United States
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Conditions
- Interventions
- First Posted Date
- 2023-11-30
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 492
- Registration Number
- NCT06152575
- Locations
- 🇺🇸
Community Health Network, Inc., Indianapolis, Indiana, United States
🇺🇸Cayuga Cancer Center at Cayuga Park, Ithaca, New York, United States
🇺🇸Cayuga Medical Center, Ithaca, New York, United States
Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2023-06-28
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT05922501
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Isa-Pom-Dex in Elderly/Frail Subjects With RRMM
- Conditions
- Interventions
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 49
- Registration Number
- NCT05911321
- Locations
- 🇺🇸
Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
🇺🇸Atrium Health Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States
🇺🇸Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Pro-miniCHOP-like Regimen for Treatment-naive Elderly Patients
- Conditions
- Interventions
- First Posted Date
- 2023-04-12
- Last Posted Date
- 2023-04-20
- Target Recruit Count
- 35
- Registration Number
- NCT05809180
- Locations
- 🇨🇳
the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2023-03-29
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 83
- Registration Number
- NCT05789303
- Locations
- 🇺🇸
University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, United States
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2023-02-15
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 380
- Registration Number
- NCT05730036
- Locations
- 🇧🇪
Ziekenhuis Netwerk Antwerpen Campus Stuivenberg, Antwerp, Belgium
🇵🇱Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie, Lublin, Lubelskie, Poland
🇺🇸UCLA, Los Angeles, California, United States
International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
- First Posted Date
- 2023-01-03
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 70
- Registration Number
- NCT05669989
- Locations
- 🇳🇿
Investigational Site Number : 5540002, Auckland, New Zealand
🇺🇸Washington University- Site Number : 8400001, Saint Louis, Missouri, United States
🇦🇺Investigational Site Number : 0360006, Blacktown, New South Wales, Australia
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory
- Conditions
- Interventions
- First Posted Date
- 2022-10-17
- Last Posted Date
- 2022-10-17
- Lead Sponsor
- Hellenic Society of Hematology
- Target Recruit Count
- 48
- Registration Number
- NCT05581875
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2022-10-07
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 650
- Registration Number
- NCT05572515
- Locations
- 🇺🇸
Michael E DeBakey VA Medical Center, Houston, Texas, United States
🇨🇦Arthur J E Child Comprehensive Cancer Centre, Calgary, Alberta, Canada
🇵🇹Uls Gaia Espinho, Vila Nova de Gaia, Portugal
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.